Literature DB >> 7515768

Allelic loss in locally metastatic, multisampled prostate cancer.

W A Sakr1, J A Macoska, P Benson, D J Grignon, S R Wolman, J E Pontes, J D Crissman.   

Abstract

In order to determine whether retention or loss of potential tumor suppressor loci that map to 8p, 10q, or 16q reflect genetic relationships among prostatic intraepithelial neoplasias (PINs), multicentric primary prostatic cancers, and regional lymph node metastases or are associated with the metastatic phenotype, we analyzed 19 cases of locally metastatic prostate carcinoma (stage D1) utilizing polymerase chain reaction techniques. In each case, tissue samples from metastatic tumor, the (dominant) primary tumor, and nonneoplastic prostatic tissue were examined. In selected cases, allelic loss in additional tumor foci, separate from the dominant tumor nodule, and areas of PIN were examined. Allelic loss of sequences on 8p, 10q, and 16q were observed in 20-29% of PINs, 18-42% of primary tumors, and 8-25% of metastatic tumors. Discrepancies in sequence dosage between histological components were most pronounced for 8p sequences, especially between the dominant tumor nodule and metastatic deposits in cases in which > or = 3 separate tumor foci/gland were identified. These results suggest that putative premalignant lesions, moderately or poorly differentiated, geographically separate primary tumor foci, and metastases within morphologically "complex" prostates (those with > or = 3 foci/gland) are likely to be more discordant for sequence dosage at 8p than those within "simpler" glands (< 3 foci/gland). Also, our results suggest that lymph node metastases may be genetically related to either the dominant or additional primary tumor foci in more complex prostates and that accumulation of genetic aberration may differ in primary and metastatic lesions.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7515768

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  29 in total

1.  Genetic analysis of prostatic atypical adenomatous hyperplasia (adenosis).

Authors:  J A Doll; X Zhu; J Furman; Z Kaleem; C Torres; P A Humphrey; H Donis-Keller
Journal:  Am J Pathol       Date:  1999-09       Impact factor: 4.307

Review 2.  Prostate cancer prevention: review of target populations, pathological biomarkers, and chemopreventive agents.

Authors:  R Montironi; R Mazzucchelli; J R Marshall; P H Bartels
Journal:  J Clin Pathol       Date:  1999-11       Impact factor: 3.411

3.  Nkx3.1 functions as para-transcription factor to regulate gene expression and cell proliferation in non-cell autonomous manner.

Authors:  Jian Zhou; Li Qin; Jean Ching-Yi Tien; Li Gao; Xian Chen; Fen Wang; Jer-Tsong Hsieh; Jianming Xu
Journal:  J Biol Chem       Date:  2012-03-31       Impact factor: 5.157

4.  Molecular sampling of prostate cancer: a dilemma for predicting disease progression.

Authors:  Andrea Sboner; Francesca Demichelis; Stefano Calza; Yudi Pawitan; Sunita R Setlur; Yujin Hoshida; Sven Perner; Hans-Olov Adami; Katja Fall; Lorelei A Mucci; Philip W Kantoff; Meir Stampfer; Swen-Olof Andersson; Eberhard Varenhorst; Jan-Erik Johansson; Mark B Gerstein; Todd R Golub; Mark A Rubin; Ove Andrén
Journal:  BMC Med Genomics       Date:  2010-03-16       Impact factor: 3.063

5.  NKX3.1 as a marker of prostatic origin in metastatic tumors.

Authors:  Bora Gurel; Tehmina Z Ali; Elizabeth A Montgomery; Shahnaz Begum; Jessica Hicks; Michael Goggins; Charles G Eberhart; Douglas P Clark; Charles J Bieberich; Jonathan I Epstein; Angelo M De Marzo
Journal:  Am J Surg Pathol       Date:  2010-08       Impact factor: 6.394

6.  Spontaneous but not experimental metastatic activities differentiate primary tumor-derived vs metastasis-derived mouse prostate cancer cell lines.

Authors:  S J Hall; T C Thompson
Journal:  Clin Exp Metastasis       Date:  1997-11       Impact factor: 5.150

7.  Fluorescence in situ hybridization evaluation of chromosome deletion patterns in prostate cancer.

Authors:  S F Huang; S Xiao; A A Renshaw; K R Loughlin; T J Hudson; J A Fletcher
Journal:  Am J Pathol       Date:  1996-11       Impact factor: 4.307

Review 8.  Precursor lesions for prostate cancer.

Authors:  M R Feneley; C Busch
Journal:  J R Soc Med       Date:  1997-10       Impact factor: 5.344

9.  Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies : early cancers may contain aggressive genetic features.

Authors:  J C Alers; P J Krijtenburg; A N Vis; R F Hoedemaeker; M F Wildhagen; W C Hop; T T van Der Kwast; F H Schröder; H J Tanke; H van Dekken
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

10.  TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications.

Authors:  Marc Barry; Sven Perner; Francesca Demichelis; Mark A Rubin
Journal:  Urology       Date:  2007-10       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.